Tag: GlobeNewswire

Transactions during 27 October 2026 – 02 November 2026
On 7 May 2026, Alm. Brand A/S announced a share buy-back program of up to DKK 593 million, as described in company announcement no. 23/2026.

The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.

The following transactions were made under the share buy-back program 27 October – 02 November 2026:

	Number of shares bought	Average purchase price	Amount (DKK)
Accumulated, last announcement 27 October 2026 28 October 2026 29 October 2026 30 October 2026 02 November 2026	19,576,795 120,000  303,000  275,000  80,000  132,997	16.57 17.68 17.74 17.22 17.20 17.31	324,350,861 2,121,684 5,376,129 4,736,050 1,375,600 2,302,125
Total, 27 October – 02 November 2026	910,997	17.47	15,911,588
Accumulated under the program	20,487,792	16.61	340,262,449

With the transactions stated above Alm. Brand A/S holds a total of 53,224,462 own shares, corresponding to 3.79% of the total number of outstanding shares.

Contact
Please direct any questions regarding this announcement to:

Investors and equity analysts:                                 

VP, Head of Investor Relations & ESG                    
Mads Thinggaard                                                       
Mobile no, +45 2025 5469                                      

Attachments

• Alm Brand_Share buyback 27 October – 02 November 2026
• AS 60 2026 – Transactions under share buyback program

MONTREAL and CHARLOTTE, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) — Milestone^® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report its financial results for the third quarter ended September 30, 2026, and provide a business update before the market open. The announcement will be followed by a conference call and webcast for investors at 8:30 am ET.

To access the live conference call, participants may register here.

Conference Details:
Conference Date:	Friday, November 13, 2026
Conference Time:	8:30 am ET
Conference Dial-in:	1-877-407-0792
International Dial-in:	1-201-689-8263
Conference ID:	13763324

Participants can use Guest dial-in #s above and be answered by an operator OR click the Call Me™ link for instant telephone access to the event. The Call me™ link will be made active 15 minutes prior to scheduled start time.

A replay of the audio webcast of the call will be available under the News & Events section of Milestone’s website, www.milestonepharma.com.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is an emerging commercial-stage biopharmaceutical company advancing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST^® (etripamil) nasal spray, a novel calcium channel blocker, which is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in Phase 3 development for the control of symptomatic episodic attacks associated with AFib.
https://milestonepharma.com/.

Contact:

Investor Relations

Kevin Gardner, kgardner@lifesciadvisors.com

Media Relations 

Rebecca Novak, rnovak@milestonepharma.com

SHENYANG, China, Nov. 03, 2026 (GLOBE NEWSWIRE) — Geely Auto Group unveiled its latest methanol hybrid powertrain technology and launched the Geely Xingyao 6 EF, the world’s first production methanol hybrid passenger vehicle. The launch of the new technology marked a significant milestone in Geely’s nearly two-decade commitment to methanol as a viable, scalable, green alternative fuel for the automotive industry.

The Geely Xingyao 6 EF is a flexible-fuel hybrid sedan capable of running on methanol, gasoline, or electricity, with the distinct capability to utilize methanol and gasoline in any mix ratio within the same fuel tank. This uniquely flexible power utilization capability addresses critical shortcomings of electric vehicles in cold climates while offering a pragmatic bridge to the adoption of green mobility.

Breaking the Cold-Climate Barrier

At the heart of this innovative new powertrain technology is Geely’s methanol hybrid engine, which achieves a thermal efficiency of 48.15%, the highest among mass-produced methanol engines globally. The engine incorporates 350-bar high-pressure direct injection and a high-power ignition system, enabling reliable cold starts at temperatures approaching minus 40℃. This capability directly addresses the severe range degradation that electric vehicles experience in northern China’s winter conditions.

The vehicle is also equipped with a methanol concentration sensor that analyzes the fuel mixture in real time through subtle electrical current changes as fuel passes through the sensor. The engine control unit then adjusts injection and ignition parameters accordingly, ensuring stable and efficient operation regardless of the methanol-to-gasoline ratio.

Performance and Efficiency

Under CLTC standards, the Geely Xingyao 6 EF offers 230 kilometers of electric range for daily urban commuting. The vehicle’s combined range with a full methanol tank and charged battery reaches approximately 1,250 km, while a full tank of gasoline and charged battery extends that range to 1,880 km.

The sedan is built on Geely’s GEA global intelligent electric architecture, featuring a 4.8-meter body length and a 2,756-millimeter wheelbase. It comes equipped with the Flyme Auto intelligent cockpit system, a comprehensive safety package, and a body structure with 71.6% high-strength steel.

Pragmatic Solutions to a Sustainable Future

Geely Auto Group’s commitment to methanol technologies is positioned within a broader multi-energy approach to sustainable mobility that includes electric, hybrid, and hydrogen technologies. The company has invested in methanol research and development since 2005 and built a complete value chain spanning methanol production, storage, transportation, refuelling infrastructure, and vehicle applications.

Development of methanol technologies also provides an advantage to Geely Auto Group in providing solutions to utilize sustainable green alcohol fuels including methanol and ethanol used in markets around the world. To further advance the market adaption of green methanol, Geely Auto Group has also developed the world’s first carbon exhaust capture system for automobiles which can facilitate the recycling of waste carbon into green methanol forming a carbon net zero closed cycle.

Geely positions the Xingyao 6 not as a replacement for electric or conventional hybrid models, but as a complementary solution that fills a critical gap in cold-climate and long-distance sustainable green mobility.

About Geely Auto Group

Geely Auto Group is a leading global automotive company headquartered in Hangzhou, China. Part of Zhejiang Geely Holding Group, Geely Auto Group develops and manufactures passenger vehicles under the Geely, Lynk & Co, and Zeekr brands.

With a strong focus on technology innovation, electrification, and sustainable mobility, Geely Auto Group operates world-class R&D centers and manufacturing facilities across China, Europe, and key international markets. The Group is committed to delivering safe, high-quality, and intelligent vehicles enabled by advanced technologies such as hybrid powertrains, full-electric architectures, smart connectivity, and autonomous driving systems.

As a global company, Geely Auto Group continues to expand its international presence through strategic partnerships, localized operations, and industry-leading platforms. Geely strives to create mobility solutions that are greener, smarter, and more accessible, driving forward the future of sustainable transportation.

Media Contact
Contact Person: Janet Chen
Email: media@geely.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6a28e03c-9817-437f-bdee-e5b054024715

To Nasdaq Copenhagen

Terms for Nykredit’s and Totalkredit’s auctions

The total bond offering in connection with the interest rate adjustment of adjustable-rate mortgages (ARMs) and the refinancing of floating-rate loans at Nykredit’s and Totalkredit’s refinancing auctions amounts to approx. DKK 42.8bn. The auctions will be conducted in the period from 16th to 20th November 2026.

In the auction period, Nykredit Realkredit A/S will publish the amounts offered in the individual ISINs daily at nykredit.com/ir.

Terms for the auctions including a list of the bonds offered, amounts offered and an auction schedule appear from Appendices 1, 2 and 3.

Questions regarding the bond sale as well as technical matters may be addressed to Nykredit Realkredit A/S, Group Treasury, Christian Mauritzen, tel +45 44 55 10 14.

Other questions may be addressed to Corporate Communications, tel +45 44 55 14 50.

Appendix 1: Auction terms

Bonds offered, amounts offered and auction schedule
Appendix 2 and 3 contains auction schedules, lists of bonds offered, expected amounts and settlement dates.

Every morning at 09:00 CET in the auction period, the amounts offered on that particular day in the individual ISINs will be published at nykredit.com/ir under “Debt”, where you can find information on the refinancing auctions.

Refinancing principles – ARMs
The Nykredit Group offers fixed-rate non-callable bullet covered bonds for interest rate adjustment of ARMs based on the “refinancing price” principle.

For interest rate adjustment at the refinancing price, the bonds are sold at one or more bond auctions. The price is fixed as a weighted average of the prices obtained at the auctions.

If the Nykredit Group finds that the amount of bonds offered at an auction is not sufficient to obtain a market-consistent price, the refinancing price will instead be based on the Consolidated Reference Price of the bond in question quoted on Nasdaq Copenhagen.

Refinancing principles – floating-rate loans
Floating-rate loans are refinanced at one stand-alone auction.

• ISIN DK000955566-6 is non-callable.
  The mortgage bond is offered and settled at a price of 100.20.
  Based on the offer price, bids must be made in terms of the reference rate spread used for the regular coupon fixing.

Reference Rate: Cita/6 months
Fixing method: Fourth last Business Day (adjusted)
Expiring ISIN: DK000954209-4 and DK0009954373-8

Credit ratings
All auctioned bonds issued through Capital Centre H are rated AAA by S&P.
All auctioned bonds issued through Capital Centre J are government-guaranteed and therefore not
rated.

Bids
Bids for fixed-rate non-callable bullet covered bonds must be made in terms of amount and price. With respect to bonds maturing within 14 months, bids must be made in prices correct to three decimals. Other bids must be made correct to two decimals.

For all DKK-denominated bonds bids must be made in multiples of DKK 100,000, and for all EUR-denominated bonds in multiples of EUR 10,000.

More than one bid may be made in the same ISIN.

Type of auction
Mortgage bonds issued through Capital Centre H will be auctioned through Nasdaq Copenhagen’s auction submarket CPH Auctions. Participants are stockbrokers and investors with access to the auction submarket at Nasdaq Copenhagen.

Bonds issued through Capital Centre J will be auctioned through Bloomberg’s auction system AUPD.
Market participants who do not already have access to this system should contact Nykredit Realkredit
A/S, Group Treasury, prior to the auctions.

Allotment
As regards bonds for which bids are made in terms of price, bids above the cut-off price will be settled in full, and bids at the cut-off price may be accepted on a pro rata basis.

With respect to bonds for which bids are made in terms of reference rate spread, bids below the cut-off spread will be settled in full, and bids at the cut-off spread may be accepted on a pro rata basis.

All trades concluded will be published through Nasdaq Copenhagen.

Allotment at the auctions will take place as soon as possible, but not later than 10 minutes after closing.

Conditional offering of bonds with interest rate trigger
A condition of the final completion of a sale (allotment) of bonds offered with an interest rate trigger is that the yield-to-maturity of the bonds will not rise by more than 5 percentage points. Reference is made to the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act.

Value date
All bonds at auction will be subject to long settlement. The value date of all trades executed at the auctions will be 4th January 2027.

Reverse facility
As the bonds traded will be subject to long settlement, Nykredit Realkredit A/S offers a reverse facility to auction participants whose bids have been accepted and who require the bonds after only two trading days.

By means of the reverse facility, Nykredit Realkredit A/S offers to sell the allotted bonds subject to the conventional two settlement days and subsequently repurchase them with 4th January 2027 as the value date.

The size of the reverse facility will be determined on an individual basis but cannot exceed the amount allotted to each individual bidder. The reverse facility can be made conditional on the investor providing a corresponding amount of bonds maturing on 1st January 2027.

Reverse facilities will be arranged on an individual basis. Please contact Nykredit Realkredit A/S, Group Treasury, Morten Willendrup, tel +45 44 55 16 92.

Reservations regarding auctions
If, contrary to expectations, technical problems should prevent Nykredit Realkredit A/S from conducting an auction through Nasdaq Copenhagen’s auction submarket, a stock exchange announcement will be issued containing the practical details of the auction.

Tap sales
Tap sales are made on 17th and 18th November 2026. Bids may be made on these days by contacting Nykredit Realkredit A/S, Group Treasury.

Other terms
The Nykredit Group is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. If a sale of bonds has to be cancelled, the market will be notified immediately by a stock exchange announcement.

Appendix 2: Settlement times and amounts offered for bonds issued through Capital Centre H.

ISIN

Capital centre

IT / RF*

Coupon

Maturity date

Bids on

Interest rate trigger

LCR level

Currency

Auction dates

Settlement

Offering (million)

Start

End

Cut-off

Allotment

DK0009515363

SDO (H)

RF

1

01-01-2028

Price

–

1b

DKK

Tapsale**

400

DK0009519357

SDO (H)

RF

1

01-01-2029

Price

–

1b

DKK

16-11-2026

10:30

10:40

900

DK0009524001

SDO (H)

RF

1

01-01-2030

Price

–

1b

DKK

17-11-2026

19-11-2026

10:30

10:40

10,800

DK0009529075

SDO (H)

RF

1

01-01-2031

Price

–

1b

DKK

16-11-2026

11:30

11:40

600

DK0009533267

SDO (H)

RF

1

01-01-2032

Price

–

1b

DKK

17-11-2026

19-11-2026

11:30

11:40

10,500

DK0009541286

SDO (H)

RF

1

01-01-2034

Price

–

non-level

DKK

Tapsale**

100

DK0009555237

SDO (H)

IT / RF*

1

01-04-2028

Price

–

1b

DKK

17-11-2026

19-11-2026

13:00

13:10

4,600

DK0009555070

SDO (H)

IT / RF*

1

01-01-2028

Price

7,40%

non-level

EUR

16-11-2026

13:00

13:10

70

DK0009546673

SDO (H)

RF

3

01-01-2030

Price

–

non-level

EUR

Tapsale**

16

DK0009555666

SDO (H)

RF

Adjustable

01-07-2030

Yield

–

1b

DKK

20-11-2026

10:30

10:40

13,900

* (IT) Interest rate and refinancing trigger / (RF) Refinancing trigger
** Tap sales are conducted on 17th and 18th November 2026.

Please note that the Nykredit Group is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. The market must be notified hereof immediately by way of a company announcement.

Appendix 3: Settlement times and amounts offered for bonds issued through Capital Centre J (Care Homes)

ISIN

Capital centre

IT / RF*

Coupon

Maturity Date

Bids on

LCR Level

Currency

Auction dates

Settlement

Offering (million)

Start

End

Cut-off

Allotment

DK0009518466

SDO (J)

RF

1

01-01-2028

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009518540

SDO (J)

RF

1

01-01-2029

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009523896

SDO (J)

RF

1

01-01-2030

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009529158

SDO (J)

RF

1

01-01-2031

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009533184

SDO (J)

RF

1

01-01-2032

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009537847

SDO (J)

RF

1

01-01-2033

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009542763

SDO (J)

RF

1

01-01-2034

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009546830

SDO (J)

RF

1

01-01-2035

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009550519

SDO (J)

RF

1

01-01-2036

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009555153

SDO (J)

RF

1

01-01-2037

Price

1a

DKK

16-11-2026

11:00

11:10

242

* (IT) Interest rate and refinancing trigger / (RF) Refinancing trigger

Please note that the Nykredit Group is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. The market must be notified hereof immediately by way of a company announcement.

Attachment

• Terms for Nykredit and Totalkredits auctions

To Nasdaq Copenhagen

Terms for Nykredit’s and Totalkredit’s auctions

The total bond offering in connection with the interest rate adjustment of adjustable-rate mortgages (ARMs) and the refinancing of floating-rate loans at Nykredit’s and Totalkredit’s refinancing auctions amounts to approx. DKK 42.8bn. The auctions will be conducted in the period from 16th to 20th November 2026.

In the auction period, Nykredit Realkredit A/S will publish the amounts offered in the individual ISINs daily at nykredit.com/ir.

Terms for the auctions including a list of the bonds offered, amounts offered and an auction schedule appear from Appendices 1, 2 and 3.

Questions regarding the bond sale as well as technical matters may be addressed to Nykredit Realkredit A/S, Group Treasury, Christian Mauritzen, tel +45 44 55 10 14.

Other questions may be addressed to Corporate Communications, tel +45 44 55 14 50.

Appendix 1: Auction terms

Bonds offered, amounts offered and auction schedule
Appendix 2 and 3 contains auction schedules, lists of bonds offered, expected amounts and settlement dates.

Every morning at 09:00 CET in the auction period, the amounts offered on that particular day in the individual ISINs will be published at nykredit.com/ir under “Debt”, where you can find information on the refinancing auctions.

Refinancing principles – ARMs
The Nykredit Group offers fixed-rate non-callable bullet covered bonds for interest rate adjustment of ARMs based on the “refinancing price” principle.

For interest rate adjustment at the refinancing price, the bonds are sold at one or more bond auctions. The price is fixed as a weighted average of the prices obtained at the auctions.

If the Nykredit Group finds that the amount of bonds offered at an auction is not sufficient to obtain a market-consistent price, the refinancing price will instead be based on the Consolidated Reference Price of the bond in question quoted on Nasdaq Copenhagen.

Refinancing principles – floating-rate loans
Floating-rate loans are refinanced at one stand-alone auction.

• ISIN DK000955566-6 is non-callable.
  The mortgage bond is offered and settled at a price of 100.20.
  Based on the offer price, bids must be made in terms of the reference rate spread used for the regular coupon fixing.

Reference Rate: Cita/6 months
Fixing method: Fourth last Business Day (adjusted)
Expiring ISIN: DK000954209-4 and DK0009954373-8

Credit ratings
All auctioned bonds issued through Capital Centre H are rated AAA by S&P.
All auctioned bonds issued through Capital Centre J are government-guaranteed and therefore not
rated.

Bids
Bids for fixed-rate non-callable bullet covered bonds must be made in terms of amount and price. With respect to bonds maturing within 14 months, bids must be made in prices correct to three decimals. Other bids must be made correct to two decimals.

For all DKK-denominated bonds bids must be made in multiples of DKK 100,000, and for all EUR-denominated bonds in multiples of EUR 10,000.

More than one bid may be made in the same ISIN.

Type of auction
Mortgage bonds issued through Capital Centre H will be auctioned through Nasdaq Copenhagen’s auction submarket CPH Auctions. Participants are stockbrokers and investors with access to the auction submarket at Nasdaq Copenhagen.

Bonds issued through Capital Centre J will be auctioned through Bloomberg’s auction system AUPD.
Market participants who do not already have access to this system should contact Nykredit Realkredit
A/S, Group Treasury, prior to the auctions.

Allotment
As regards bonds for which bids are made in terms of price, bids above the cut-off price will be settled in full, and bids at the cut-off price may be accepted on a pro rata basis.

With respect to bonds for which bids are made in terms of reference rate spread, bids below the cut-off spread will be settled in full, and bids at the cut-off spread may be accepted on a pro rata basis.

All trades concluded will be published through Nasdaq Copenhagen.

Allotment at the auctions will take place as soon as possible, but not later than 10 minutes after closing.

Conditional offering of bonds with interest rate trigger
A condition of the final completion of a sale (allotment) of bonds offered with an interest rate trigger is that the yield-to-maturity of the bonds will not rise by more than 5 percentage points. Reference is made to the Danish Mortgage-Credit Loans and Mortgage-Credit Bonds etc. Act.

Value date
All bonds at auction will be subject to long settlement. The value date of all trades executed at the auctions will be 4th January 2027.

Reverse facility
As the bonds traded will be subject to long settlement, Nykredit Realkredit A/S offers a reverse facility to auction participants whose bids have been accepted and who require the bonds after only two trading days.

By means of the reverse facility, Nykredit Realkredit A/S offers to sell the allotted bonds subject to the conventional two settlement days and subsequently repurchase them with 4th January 2027 as the value date.

The size of the reverse facility will be determined on an individual basis but cannot exceed the amount allotted to each individual bidder. The reverse facility can be made conditional on the investor providing a corresponding amount of bonds maturing on 1st January 2027.

Reverse facilities will be arranged on an individual basis. Please contact Nykredit Realkredit A/S, Group Treasury, Morten Willendrup, tel +45 44 55 16 92.

Reservations regarding auctions
If, contrary to expectations, technical problems should prevent Nykredit Realkredit A/S from conducting an auction through Nasdaq Copenhagen’s auction submarket, a stock exchange announcement will be issued containing the practical details of the auction.

Tap sales
Tap sales are made on 17th and 18th November 2026. Bids may be made on these days by contacting Nykredit Realkredit A/S, Group Treasury.

Other terms
The Nykredit Group is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. If a sale of bonds has to be cancelled, the market will be notified immediately by a stock exchange announcement.

Appendix 2: Settlement times and amounts offered for bonds issued through Capital Centre H.

ISIN

Capital centre

IT / RF*

Coupon

Maturity date

Bids on

Interest rate trigger

LCR level

Currency

Auction dates

Settlement

Offering (million)

Start

End

Cut-off

Allotment

DK0009515363

SDO (H)

RF

1

01-01-2028

Price

–

1b

DKK

Tapsale**

400

DK0009519357

SDO (H)

RF

1

01-01-2029

Price

–

1b

DKK

16-11-2026

10:30

10:40

900

DK0009524001

SDO (H)

RF

1

01-01-2030

Price

–

1b

DKK

17-11-2026

19-11-2026

10:30

10:40

10,800

DK0009529075

SDO (H)

RF

1

01-01-2031

Price

–

1b

DKK

16-11-2026

11:30

11:40

600

DK0009533267

SDO (H)

RF

1

01-01-2032

Price

–

1b

DKK

17-11-2026

19-11-2026

11:30

11:40

10,500

DK0009541286

SDO (H)

RF

1

01-01-2034

Price

–

non-level

DKK

Tapsale**

100

DK0009555237

SDO (H)

IT / RF*

1

01-04-2028

Price

–

1b

DKK

17-11-2026

19-11-2026

13:00

13:10

4,600

DK0009555070

SDO (H)

IT / RF*

1

01-01-2028

Price

7,40%

non-level

EUR

16-11-2026

13:00

13:10

70

DK0009546673

SDO (H)

RF

3

01-01-2030

Price

–

non-level

EUR

Tapsale**

16

DK0009555666

SDO (H)

RF

Adjustable

01-07-2030

Yield

–

1b

DKK

20-11-2026

10:30

10:40

13,900

* (IT) Interest rate and refinancing trigger / (RF) Refinancing trigger
** Tap sales are conducted on 17th and 18th November 2026.

Please note that the Nykredit Group is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. The market must be notified hereof immediately by way of a company announcement.

Appendix 3: Settlement times and amounts offered for bonds issued through Capital Centre J (Care Homes)

ISIN

Capital centre

IT / RF*

Coupon

Maturity Date

Bids on

LCR Level

Currency

Auction dates

Settlement

Offering (million)

Start

End

Cut-off

Allotment

DK0009518466

SDO (J)

RF

1

01-01-2028

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009518540

SDO (J)

RF

1

01-01-2029

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009523896

SDO (J)

RF

1

01-01-2030

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009529158

SDO (J)

RF

1

01-01-2031

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009533184

SDO (J)

RF

1

01-01-2032

Price

1a

DKK

16-11-2026

11:00

11:10

18

DK0009537847

SDO (J)

RF

1

01-01-2033

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009542763

SDO (J)

RF

1

01-01-2034

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009546830

SDO (J)

RF

1

01-01-2035

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009550519

SDO (J)

RF

1

01-01-2036

Price

1a

DKK

16-11-2026

11:00

11:10

19

DK0009555153

SDO (J)

RF

1

01-01-2037

Price

1a

DKK

16-11-2026

11:00

11:10

242

* (IT) Interest rate and refinancing trigger / (RF) Refinancing trigger

Please note that the Nykredit Group is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. The market must be notified hereof immediately by way of a company announcement.

Attachment

• Terms for Nykredit and Totalkredits auctions

• Study demonstrates feasibility of saline-based hybrid IVUS-OCT imaging without iodinated contrast during image acquisition
• FDA-cleared OCTIV system now in commercial clinical use, with patient cases ongoing

TORONTO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company developing imaging technologies to guide cardiovascular procedures, today announced the presentation of data from its OCTIV™ hybrid IVUS–OCT imaging system at Transcatheter Cardiovascular Therapeutics (“TCT”) 2026. The study, conducted in an animal model before OCTIV’s use in patients, demonstrated the feasibility of using saline instead of iodinated contrast during image acquisition. The FDA-cleared system is now in commercial clinical use, with its first U.S. placement completed and patient cases ongoing. The findings were presented by Megha Prasad, MD, MS, in an abstract titled “Saline-Based Hybrid IVUS-OCT Imaging: Feasibility of Contrast-Free Dual-Modality Intracoronary Imaging in a Porcine Model.”

“These findings highlight the potential of OCTIV to provide complementary ultrasound and optical images using saline, eliminating the need for iodinated contrast during image acquisition,” said Thomas Looby, President and Chief Executive Officer of Conavi Medical. “Since this study was conducted, OCTIV has advanced into commercial clinical use, with our first U.S. placement completed and patient cases ongoing. We are pleased to share these results as we build clinical experience with the system.”

Study Results

The prospective feasibility study evaluated hybrid intravascular ultrasound (“IVUS”) and optical coherence tomography (“OCT”) imaging of major coronary arteries in three swine, using saline as the sole OCT flushing medium. Investigators performed 26 imaging pullbacks in native vessels and following stent placement, assessing feasibility, safety, catheter performance and image quality.

Key findings included:

• Interpretable images across all 26 pullbacks: Hybrid imaging was successfully performed in all targeted vessels without iodinated contrast during image acquisition.
• Complementary vessel assessment: OCT provided high-resolution visualization of luminal morphology and stent architecture, while IVUS enabled assessment of vessel dimensions and deeper wall structures within the same pullback.
• Continuous IVUS imaging: IVUS assessment remained available independently of blood clearance, with high-resolution OCT visualization achieved when saline flushing was adequate.
• No observed device-related complications: No device-related complications, coronary injury, sustained arrhythmia or procedural mortality occurred.
• Potential to eliminate iodinated contrast during image acquisition: The findings support further clinical evaluation of saline-based hybrid imaging, which could be particularly relevant for patients at risk of contrast-associated acute kidney injury.  

About Conavi Medical
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented OCTIV hybrid imaging system is the first system to co-register and co-align intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging beams to enable simultaneous hybrid imaging of coronary arteries. The hybrid imaging system has 510(k) clearance from the U.S. Food and Drug Administration. For more information, visit http://www.conavi.com/.

Forward-Looking Statements
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding the Company and its business, which may include, but are not limited to, statements with respect to the anticipated clinical benefits and performance of OCTIV, continued clinical use, placements at additional U.S. institutions, participation in TCT 2026, the commercialization and commercial launch of Conavi’s hybrid imaging system and the timing thereof, the sufficiency of Conavi’s resources to achieve such commercial launch, the global market opportunity for coronary intravascular imaging (including for IVUS and OCT), the continued growth in adoption of and in the clinical validation and guideline support for intravascular imaging and the ability of Conavi’s hybrid imaging system to meet market needs. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking information or statements”. Often but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate” or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the “Risk Factors” section of the annual information form of the Company dated February 26, 2026 (available on the Company’s profile at www.sedarplus.ca). Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Contact
Mark Quick, Chief Financial Officer | 416-483-0100
Christina Cameron, Investor Relations | 416-483-0100 ext. 121 | IR@conavi.com
Susan Thomas, Media | 619-540-9195

Seasonal Initiative Builds on Established Relationship with Leading Regional Grocery Retailer

BELVIDERE, NJ, Nov. 03, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that it has secured a fresh herb program with Weis Markets for the upcoming 2026 holiday season. Building on its established relationship with the regional grocery retailer, the program provides an opportunity for Edible Garden to increase seasonal sales while reinforcing its position as a trusted supplier of fresh, high-quality herbs throughout the Mid-Atlantic region.

The holiday program builds on Edible Garden’s established relationship with Weis Markets, which includes fresh potted living herbs, hydroponic basil, and cut herb varieties. With consumer demand for fresh culinary herbs typically increasing around Thanksgiving and the December holidays, the seasonal program provides an additional opportunity to support Weis Markets’ customers during one of the most important selling periods for the category. Edible Garden’s established distribution infrastructure and proximity to Weis Markets’ core markets position the Company to respond efficiently to seasonal demand while maintaining its focus on product freshness, quality, and sustainability.

“Securing this holiday program with Weis Markets reflects the strength of our relationship and our ability to support retail partners during critical selling periods,” said Jim Kras, Chief Executive Officer of Edible Garden. “We have worked to establish Edible Garden as a reliable supplier by consistently delivering the quality, freshness, and service our retail customers expect. With our Belvidere facility strategically located near Weis Markets’ core markets, we believe we are well positioned to meet increased holiday demand while maintaining the efficiency and sustainability that distinguish our operations. This program also presents an opportunity to generate incremental sales and further demonstrate the value of our regional growing and distribution capabilities.”

The Weis Markets holiday program highlights the importance of Edible Garden’s established retail partnerships in supporting its long-term growth strategy. As the Company continues to build its presence in the fresh herb category, seasonal programs such as this provide opportunities to increase sales, deepen customer relationships, and strengthen its competitive position in key regional markets.

ABOUT EDIBLE GARDEN^®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired^® next-generation farming model. Available in over 6,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. The Company is also expanding its Prairie Hills facility in Webster City, Iowa, into a dedicated ready-to-drink (RTD) clean nutrition manufacturing hub, supporting its Farm-to-Formula® strategy and its transformation into higher-margin, shelf-stable nutrition categories.

Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).

The Company has been recognized as a FoodTech 500 firm by Forward Fooding, is a multi-year participant in Walmart’s Project Gigaton and a Giga Guru designee and has received NRG’s Excellence in Energy Award for its commitment to measurable environmental performance and energy stewardship. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way^® and Vitamin Whey^®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.

Learn more at https://ediblegardenag.com.
For Pulp products, visit https://www.pulpflavors.com.
For Vitamin Whey® products, visit https://vitaminwhey.com.
For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/.
Watch the Company’s latest corporate video here.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believe,” “expect,” “intend,” “plan,” “expand,” “advance,” “designed to,” “opportunity,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements include, without limitation, statements regarding the Company’s holiday fresh herb program with Weis Markets, the Company’s ability to expand its presence and capture additional market share in its key markets, the Company’s available capacity and ability to service additional retail volume, the Company’s ability to deepen its relationship with Weis Markets and other major retailers, and the Company’s Farm-to-Formula® strategy. There can be no assurance that the holiday program or the Company’s distribution center awards will result in the anticipated volume, revenue or market share gains. Forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including those described in the “Risk Factors” section and other sections of the Company’s reports filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:
Crescendo Communications, LLC
212-671-1020
EDBL@crescendo-ir.com

Decades of experience growing dual-use defense technology companies 

Trusted senior intelligence leader, with a record of accomplishment across strategic, tactical and policy roles

Former CEO of Constellis and Tenax Aerospace, global leaders in applied geospatial technology

DENVER, Nov. 03, 2026 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in geospatial intelligence powered by proprietary 3D data, rapid image processing software and AI-driven analytics, today announced the appointment of Mr. Terry Ryan to its Board of Directors.

Mr. Ryan brings decades of experience in geospatial intelligence as a former federal official and defense and intelligence executive. Mr. Ryan served as a corporate senior executive of high-growth public and private defense technology companies, including Science Applications International Corp. (SAIC), the predecessor of Leidos Holdings, Inc., ManTech, Mercury Systems, VT Services, SRA International and Tenax Aerospace, all of which provide or provided geospatial-related support services to federal customers.

Mr. Ryan has advised past directors of the CIA, the Joint Chiefs of Staff and the Defense Advanced Research Projects Agency (DARPA) on advanced GEOINT solutions. As a former professional staff member of the U.S. Senate and House Intelligence oversight committees, Director, Intelligence Surveillance and Reconnaissance Systems, Office of Secretary of Defense and Deputy Director of the Defense Airborne Reconnaissance Office, Mr. Ryan has overseen the allocation of billions of dollars to develop and integrate airborne and spaceborne multi-domain sensor platforms. Most recently, as CEO and director of Constellis corporation, Mr. Ryan led the development of Constellis’ LEXSO, a layered AI decision-support platform that integrates multi-domain sensor data on geospatial foundational layers to enhance real-time situational awareness for the protection of critical infrastructure, globally. This appointment supports Intermap’s continued investment in integrating its global-scale airborne and spaceborne GEOINT across multi-domain operations. Mr. Ryan continues to support Constellis’ global operations and deployment of the LEXSO platform as Executive Vice Chairman.

“We are delighted to welcome Terry to Intermap’s Board as we expand our multi-domain product suite,” said Patrick A. Blott, Chairman and Chief Executive Officer of Intermap Technologies. “Terry has built and led world-class defense technology companies, focused on deploying integrated sensor capabilities in space, air, land and sea to produce autonomous geospatial intelligence. His deep relationships across government and institutional investors will strengthen Intermap as we pursue new opportunities around the world.”

“Intermap has built a differentiated geospatial intelligence platform that integrates sensors to address critical latency and autonomy challenges for government and commercial customers,” said Terry Ryan. “The Company has established a strong foundation for growth, combining proprietary global-scale 3D terrain data with advanced spaceborne image processing and AI decision support. I look forward to working with the Board and management team to help advance Intermap’s strategy, broaden access to growth capital and create long-term value for shareholders.”

To facilitate the appointment of Mr. Ryan to the Board of Directors of Intermap prior to the next annual meeting of shareholders, Mr. Philippe Frappier has graciously agreed to step down as a director of Intermap and will continue as a Board observer and advisor during the interim period. It is expected that Mr. Frappier will be nominated for election with the existing directors of Intermap at the next annual meeting of shareholders.

Intermap Reader Advisory 
Certain information contained in this news release, including statements regarding Mr. Ryan’s anticipated contributions to the Company, the expected benefits of his appointment and the Company’s growth opportunities, constitutes forward-looking information or forward-looking statements under applicable securities laws. Words such as “anticipate,” “expect,” “project,” “estimate,” “forecast,” “will,” “may,” “intend,” “plan,” “believe” and similar expressions are intended to identify forward-looking statements. Although Intermap believes these statements are based on information and assumptions that are current, reasonable and complete, they are necessarily subject to a variety of known and unknown risks and uncertainties. Intermap’s forward-looking statements are subject to risks and uncertainties relating to, among other matters, cash available to fund operations, access to capital, revenue fluctuations, the nature of government contracts, economic conditions, the loss of key customers, the retention and availability of executive talent, competing technologies, common-share price volatility, the loss of proprietary information, software functionality, internet and systems infrastructure, information technology security, the breakdown of strategic alliances and international and political considerations. Additional risks and uncertainties are discussed in Intermap’s Annual Information Form and other securities filings. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those anticipated. Accordingly, no assurance can be given that the events or results contemplated by the forward-looking statements will occur. All forward-looking statements attributable to Intermap or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement. The forward-looking statements in this news release are made as of its date, and the Company undertakes no obligation to update or revise them publicly, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

About Intermap Technologies
Intermap Technologies is a global leader in geospatial intelligence powered by proprietary 3D data and AI-driven analytics. The Company delivers actionable intelligence to government and commercial customers through a portfolio of applications, platforms and solutions that support risk management, infrastructure planning, operational readiness and mission-critical decision-making. Intermap’s proprietary 3D data foundation spans more than 300 million square kilometers across over 150 countries and powers intelligence solutions for government, insurance, aviation, telecommunications, transportation, renewable energy, agriculture, natural resources and space markets. Through advanced analytics, automated processing and enterprise-scale data delivery, Intermap helps organizations transform complex geospatial information into decision-ready intelligence.

For more information, please visit www.intermap.com or contact:
Jennifer Bakken
Executive Vice President and CFO
CFO@intermap.com
+1 (303) 708-0955

Sean Peasgood
Investor Relations
Sean@SophicCapital.com
+1 (647) 260-9266

LOUISVILLE, Ky., Nov. 03, 2026 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the three months ended September 30, 2026 before the market open on Monday, November 16, 2026. A conference call to review the results is scheduled for Monday, November 16, 2026, at 9:00 am Eastern Time, which will include prepared remarks and materials from management followed by a live Q&A. The call will be hosted by Rick Mills, Chairman and Chief Executive Officer, Tamra Koshewa, Chief Financial Officer and George Sautter, Chief Strategy Officer.

Prior to the call, participants should register at https://bit.ly/CREXearnings3Q2026. Once registered, participants can use the weblink provided in the registration email to participate in the live webcast.  An archived edition of the earnings conference call will be posted on our website and will remain available for one year.

About Creative Realities, Inc.
Creative Realities designs, develops and deploys digital signage-based experiences for enterprise-level networks utilizing its Clarity™, ReflectView™, and iShowroom™ Content Management System (CMS) platforms. The Company is actively providing recurring SaaS and support services across diverse vertical markets, including but not limited to retail, automotive, digital-out-of-home (DOOH) advertising networks, convenience stores, foodservice/QSR, gaming, theater, and stadium venues. In addition, the Company assists clients in utilizing place-based digital media to achieve business objectives such as increased revenue, enhanced customer experiences, and improved productivity. This includes the design, deployment, and day to day management of Retail Media Networks to monetize on-premise foot traffic utilizing its AdLogic™ and AdLogic CPM+™ programmatic advertising platforms.

Cautionary Note on Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and includes, among other things, discussions of our business strategies, product releases, future operations and capital resources. Words such as “estimates,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. Forward-looking statements are not guarantees of future performance, conditions or results. They are based on the opinions, estimates and beliefs of management as of the date such statements are made, and they are subject to known and unknown risks, uncertainties, assumptions and other factors, many of which are outside of our control, that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. Some of these risks are discussed in the “Risk Factors” section contained in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s subsequent filings with the U.S. Securities and Exchange Commission. Important factors, among others, that may affect actual results or outcomes include: our ability to integrate the acquired business operations of Cineplex Digital Media Inc. (“CDM”) into our own, maintain or improve the financial performance of CDM’s business and realize anticipated synergies, our strategy for customer retention, growth, product development, market position, financial results and reserves, our ability to execute on our business plan, our ability to retain key personnel, our ability to remain listed on the Nasdaq Capital Market, our ability to realize the revenues included in our future guidance and backlog reports, our ability to satisfy our upcoming debt obligations and other liabilities, the ability of the Company to continue as a going concern, potential litigation, supply chain shortages, and general economic and market conditions impacting demand for our products and services. Readers should not place undue reliance upon any forward-looking statements. We assume no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

Media:
Idea Grove
creativerealities@ideagrove.com

Investor Relations:
Chris Witty, Darrow Associates
646-438-9385
cwitty@darrowir.com

ir@cri.com
https://investors.cri.com

PALO ALTO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that two moderated posters and three posters on acoramidis and transthyretin amyloid cardiomyopathy (ATTR-CM), along with one BridgeBio-supported poster presentation led by Abbott Laboratories, will be shared at the American Heart Association (AHA) Scientific Sessions 2026, taking place in Chicago, Illinois on November 6-9, 2026. The data further strengthen the differentiated clinical profile of acoramidis, reinforcing it as the first-line treatment of choice for individuals with ATTR-CM. Acoramidis is the only selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

Acoramidis is approved as Attruby® by the U.S. FDA and is approved as BEYONTTRA® by the European Medicines Agency (EMA), Japanese Pharmaceuticals and Medical Devices Agency, Swissmedic, the Swiss Agency for Therapeutic Products, the UK Medicines and Healthcare Products Regulatory Agency, the Brazilian Health Regulatory Agency (ANVISA), and the Australian Therapeutic Goods Administration (TGA) with all labels specifying near-complete stabilization of TTR.

Moderated Posters:
Bridging the Diagnostic Gap in Transthyretin Cardiac Amyloidosis (ATTR-CM): Enhancing ATTR-CM Detection at the Time of Heart Failure Diagnosis in Women Through Sex-Specific ATTR Models (SS-ATTR-CMs)
Presenter: Hyewon Jeong, M.D., M.S., Massachusetts Institute of Technology, U.S.
Date/time: Monday, November 9 at 9:50 am CT

Artificial Intelligence for the Screening of ATTR Cardiomyopathy in the U.S.: A Multicenter Analysis from the TRACE-AI Network
Presenter: Bruno Batinica, MBChB, Yale School of Medicine, U.S.
Date/time: Monday, November 9 at 11:20 am CT

Posters:
Effects of Acoramidis on Heart Failure Events in Transthyretin Amyloid Cardiomyopathy: Results from ATTRibute-CM
Presenter: Mazen Hanna, M.D., Cleveland Clinic, U.S.
Date/time: Sunday, November 8 at 3:15 pm CT

Risk of Multiple Cardiovascular-Related Hospitalizations and of All-Cause Mortality in Transthyretin Amyloid Cardiomyopathy: Findings from ATTRibute-CM Using Multistate Modeling
Presenter: Justin L. Grodin, M.D., UT Southwestern Medical Center, U.S.
Date/time: Sunday, November 8 at 3:15 pm CT

Recovery After Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights from an N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Analysis of the ATTRibute-CM Study
Presenter: Prem Soman, M.D., University of Pittsburgh Medical Center, U.S.
Date/time: Sunday, November 8 at 3:15 pm CT

Abbott Laboratories-Led, BridgeBio-Supported Poster Presentation:
Detection of Tetrameric Transthyretin by ARCHITECT c and Alinity c Assays
Presenter: Lici A. Schurig Briccio, Ph.D., Abbott Laboratories, U.S.
Date/time: Monday, November 9 at 9:36 am CT

About Attruby® (acoramidis)
INDICATION
Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

IMPORTANT SAFETY INFORMATION
Adverse Reactions
Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation. Discontinuation rates due to adverse events were similar between patients treated with Attruby versus placebo (9.3% and 8.5%, respectively).

About BridgeBio
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube and TikTok.

BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650) 789-8220

BridgeBio Investor Contact:
BridgeBio Investor Relations
ir@bridgebio.com